TY - JOUR
T1 - Short Communication: Protective Efficacy of Broadly Neutralizing Antibody PGDM1400 Against HIV-1 Challenge in Humanized Mice
AU - van der Velden, Yme U.
AU - Villaudy, Julien
AU - Siteur-van Rijnstra, Esther
AU - van der Linden, Cynthia A.
AU - Frankin, Esmay
AU - Weijer, Kees
AU - Schermer, Edith
AU - Vink, Monique A.
AU - Berkhout, Ben
AU - Sanders, Rogier W.
AU - van Gils, Marit J.
PY - 2018
Y1 - 2018
N2 - Broadly neutralizing antibodies (bNAbs) such as PGDM1400 show promise as prophylactic and therapeutic agents against HIV-1. Human immune system mice were passively immunized with different doses of PGDM1400 and challenged 24 h later with a high dose of HIV-1JRCSF. We found that PGDM1400 provided protection against HIV-1 challenge in a concentration dependent manner and that the protective concentration in blood was ∼75-fold higher than the in vitro 50% inhibitory concentration. The results demonstrate that PGDM1400 might be a promising component of strategies to prevent HIV-1 infection and provide support for the pursuit of vaccines that induce PGDM1400-like bNAbs.
AB - Broadly neutralizing antibodies (bNAbs) such as PGDM1400 show promise as prophylactic and therapeutic agents against HIV-1. Human immune system mice were passively immunized with different doses of PGDM1400 and challenged 24 h later with a high dose of HIV-1JRCSF. We found that PGDM1400 provided protection against HIV-1 challenge in a concentration dependent manner and that the protective concentration in blood was ∼75-fold higher than the in vitro 50% inhibitory concentration. The results demonstrate that PGDM1400 might be a promising component of strategies to prevent HIV-1 infection and provide support for the pursuit of vaccines that induce PGDM1400-like bNAbs.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85053671882&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30003812
U2 - https://doi.org/10.1089/aid.2018.0114
DO - https://doi.org/10.1089/aid.2018.0114
M3 - Article
C2 - 30003812
SN - 0889-2229
VL - 34
SP - 790
EP - 793
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
IS - 9
ER -